Pharmaceutical composition for adjunctively treating cancer

a technology of pharmaceutical compositions and cancer cells, applied in the field of medical compositions, to achieve the effect of lowering the cell viability of a specific cancer cell

Inactive Publication Date: 2017-11-23
TAIWAN INDIGENA BOTANICA CO LTD +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0019]In the aforesaid third embodiment of the pharmaceutical composition for adjunctively treating cancer, the pharmaceutical composition is able to lower the cell viability of a specific cancer ce

Problems solved by technology

Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceut

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for adjunctively treating cancer
  • Pharmaceutical composition for adjunctively treating cancer
  • Pharmaceutical composition for adjunctively treating cancer

Examples

Experimental program
Comparison scheme
Effect test

first embodiment

[0027]the pharmaceutical composition for adjunctively treating cancer is a Taiwanofungus camphorata extract, wherein the Taiwanofungus camphorata extract is a water extract of Taiwanofungus camphorata (TCWE) or an ethanol extract of Taiwanofungus camphorata (TCEE).

[0028]In the present invention, the TCEE is taken as an exemplary embodiment for proving the therapeutic effect of the pharmaceutical composition to a specific cancer. The TCEE is fabricated by using following processing steps:[0029]step (1): preparing 10-gram dried fruiting body of a Taiwanofungus camphorata, and using ethanol of 400 mL to treating the dried fruiting bodies with a first extracting process under 45-60° C., for 24 hours;[0030]step (2): filtering a first extract liquid collected from the step (1), and then obtaining a first filtrate liquid and a post-extraction residue of the Taiwanofungus camphorata; [0031]step (3): using ethanol of 400 mL to treating the post-extraction residue with a second extracting pro...

second embodiment

[0036]As the person skilled in fungus technology field well knows, Lingzhi mushroom (or Reishi mushroom) is considered to be Ganodermataceae in a board sense. However, in the narrow sense, Lingzhi mushroom means some special species be widely cultivated. Lingzhi mushroom is found having a variety of healthcare effects, and can be divided into red mushroom (Ganoderma lucidum), yellow mushroom, white mushroom, green mushroom, black mushroom, and purple mushroom. the pharmaceutical composition for adjunctively treating cancer is a Ganoderma lucidum extract, wherein the Ganoderma lucidum extract is a water extract of Ganoderma lucidum (GLWE) or an ethanol extract of Ganoderma lucidum (GLEE). Moreover, in the present invention, the GLEE is taken as an exemplary embodiment for proving the therapeutic effect of the pharmaceutical composition to a specific cancer. The GLEE is fabricated by using above-mentioned processing steps.

[0037]In order to find suitable dose for medical use of the TCE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a pharmaceutical composition for adjunctively treating cancer. Differing from conventional therapies commonly using anti-cancer drugs and/or radiation substances to cause the apoptosis of cancer cells, the present invention particularly adopts an ethanol extract of Taiwanofungus camphorata (TCEE), an ethanol extract of Ganoderma lucidum (GLEE) or a combination of the TCEE and the GLEE as the a novel pharmaceutical composition for causing the apoptosis of lung cancer cells A594, hepatoma cells Huh 7, breast cancer cells MDA-MB 231, and colorectal cancer cells HT 29. Moreover, differing from conventionally-used anti-cancer drugs and radiation substances always causing some side-effects such as nausea, vomit, and poor appetite, this novel pharmaceutical composition can not only be used for adjunctively treating cancer, but also possesses many healthy effects, including: detoxification, enhancing immunity, and increasing appetite.

Description

BACKGROUND OF THE INVENTION1. Field of the Invention[0001]The present invention relates to the technology field of medically-used compositions, and more particularly to an ethanol extract of Taiwanofungus camphorata (TCEE) and / or an ethanol extract of Ganoderma lucidum (GLEE) adopted as a pharmaceutical composition for adjunctively treating cancer.2. Description of the Prior Art[0002]Census report made by Health and Welfare Ministry of Taiwan indicates that, the number of Taiwanese suffered with cancer in 2013 has increased 2499 compared to last year. Moreover, it is worth noting that, summation of the numbers of Taiwanese suffered with colorectal cancer, lung cancer, liver cancer, and breast cancer is about 50 percent of the total cancer patients.[0003]Currently, the primary therapeutic treatment for lung cancer is surgical removal. However, most people are not diagnosed with lung cancer until late in the disease process. So that, after removing the major lesions of lung cancer, th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/074A61K36/07
CPCA61K36/074A61K2236/33A61K2236/331A61K36/07A61P35/00
Inventor SU, CHING-HUATAI, CHENG-JENGSHI, YEU-CHING
Owner TAIWAN INDIGENA BOTANICA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products